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Mutations in PTPRQ Are a Cause of Autosomal-Recessive
Nonsyndromic Hearing Impairment DFNB84
and Associated with Vestibular Dysfunction
Margit Schraders,1,2,3 Jaap Oostrik,1,2,3 Patrick L.M. Huygen,1 Tim M. Strom,4 Erwin van Wijk,1,2,3
Henricus P.M. Kunst,1,3 Lies H. Hoefsloot,5 Cor W.R.J. Cremers,1,3 Ronald J.C. Admiraal,1,3
and Hannie Kremer1,2,3,*
We identiﬁed overlapping homozygous regions within the DFNB84 locus in a nonconsanguineous Dutch family and a consanguineous
Moroccan family with sensorineural autosomal-recessive nonsyndromic hearing impairment (arNSHI). The critical region of 3.17 Mb
harbored the PTPRQ gene and mouse models with homozygous mutations in the orthologous gene display severe hearing loss. We
show that the human PTPRQ gene was not completely annotated and that additional, alternatively spliced exons are present at the
50 end of the gene. Different PTPRQ isoforms are encoded with a varying number of ﬁbronectin type 3 (FN3) domains, a transmembrane
domain, and a phosphatase domain. Sequence analysis of the PTPRQ gene in members of the families revealed a nonsense mutation in
the Dutch family and a missense mutation in the Moroccan family. The missense mutation is located in one of the FN3 domains. The
nonsense mutation results in a truncated protein with only a small number of FN3 domains and no transmembrane or phosphatase
domain. Hearing loss in the patients with PTPRQ mutations is likely to be congenital and moderate to profound and most severe in
the family with the nonsense mutation. Progression of the hearing loss was observed in both families. The hearing loss is accompanied
by vestibular dysfunction in all affected individuals. Although we show that PTPRQ is expressed in many tissues, no symptoms other
than deafness were observed in the patients.Mutations in GJB2 (MIM *121011) are a frequent cause of
autosomal-recessive nonsyndromic hearing impairment
(arNSHI, MIM 220700) in nonconsanguineous popula-
tions in the US and Europe, especially in the Mediterra-
nean region.1,2 For other arNSHI genes, the relevance for
disease in speciﬁc populations is largely unexplored. We
aimed to unravel genetic defects underlying arNSHI in
Dutch families in which mutations in GJB2 had been
excluded previously. The Dutch population is generally
regarded to be a mixed population with only a few rela-
tively genetically isolated populations including that of
the former island Urk. However, recent studies on the
elucidation of genetic defects in patients with autosomal-
recessive retinal degeneration and arNSHI have indicated
that the population in the Netherlands is not fully mixed
and that subpopulations exist in which disease-causing
mutations are present in chromosomal regions that are
identical by descent (IBD)3 (H.K., C.W.R.J.C., H.P.M.K.,
P.L.M.H., unpublished results).4,5 We selected 80 familial
cases from 38 families and 35 isolated cases with putative
arNSHI for homozygosity mapping. There were no indica-
tions for nongenetic causes of the hearing impairment in
these patients, and GJB2 was excluded as the causative
gene by sequence analysis. The large majority of the
patients was of Dutch descent. The study was approved
by the local medical ethics committee and adhered to the
tenets of the Declaration of Helsinki. Written informed1Department of Otorhinolaryngology, Head and Neck Surgery, Radboud Un
2Nijmegen Centre forMolecular Life Sciences, RadboudUniversity Nijmegen, 6
and Behaviour, RadboudUniversity Nijmegen, 6525 GANijmegen, The Netherl
Research Center for Environmental Health, 85764 Neuherberg, Germany; 5Dep
6525 GA Nijmegen, The Netherlands
*Correspondence: h.kremer@antrg.umcn.nl
DOI 10.1016/j.ajhg.2010.02.015. ª2010 by The American Society of Human
604 The American Journal of Human Genetics 86, 604–610, April 9, 2consent was obtained from all subjects or, in case of chil-
dren, from their parents.
High-resolution SNP genotyping was performed with
Affymetrix Genechip Genome-Wide Human Arrays 5.0
or Affymetrix mapping 250K single-nucleotide polymor-
phism (SNP) arrays on genomic DNA isolated from periph-
eral blood samples via standard procedures. For both array
types, the Genotyping Console software (Affymetrix) was
employed for allele calling and calculation of the regions
of homozygosity was performed with Genotyping Console
software and Partek Genomics Solution Software for the
250K and 5.0 array, respectively. On the long arm of chro-
mosome 12, a homozygous region of 3.17 Mb was shared
by all four affected members of families W04-083 and
W07-0455 (Figure 1). The parents in family W04-083 are
of Moroccan origin and are ﬁrst cousins. In this family
we identiﬁed 18 IBD regions that were larger than 1 Mb
and shared by the two sibs. The largest homozygous region
of 33.32 Mb was located at 12q21.1-q23.3 (ﬂanking SNPs:
SNP_A-2246676 and SNP_A-1937576). The two affected
subjects in family W07-0455 of Dutch origin shared in
total nine IBD regions larger than 1 Mb. Also for this
family, the region on chromosome 12q21.31 (3.17 Mb,
ﬂanking SNPs: SNP_A-4277907 and SNP_A-1835105) was
the largest homozygous region shared by the affected indi-
viduals. During the course of the project, it appeared that
the critical region on chromosome 12q21.31 was locatediversity Nijmegen Medical Centre, 6525 GA Nijmegen, The Netherlands;
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Figure 1. Homozygous Regions in the DFNB84 Locus
Schematic overview of the chromosomal region 12q14.1-q24.11 showing the DFNB84 locus (gray bar) and the homozygous regions
(black bars) identiﬁed in families W07-0455 and W04-083. The homozygous region of individual II.6 of W07-0455 delimits the region
to 3.17 Mb. Mb positions and chromosome bands are according to the UCSC genome browser (GRCh37). The shared homozygous
region contains, among others, the PTPRQ gene.in the novel deafness locus DFNB84 (Figure 1), identiﬁed
in two Palestinian families with arNSHI.6 The shared
3.17 Mb region encompasses 12 genes (Figure 1) of which
PTPRQ (MIM *603317) was the most obvious candidate
gene because defects of Ptprq are associated with deafness
in mice.7
At the time we identiﬁed the candidate interval contain-
ing the PTPRQ gene, only four exons of PTPRQ were
annotated in the UCSC Genome Browser (uc001sze.1,
NCBI Build 36.1; hg18 annotation tracks, March 2006)
and in Uniprot the human protein sequence Q9UMZ3
(Figure 2A) was available. Therefore, we initiated the char-
acterization of the human PTPRQ gene. We performed
RT-PCR and rapid ampliﬁcation of cDNA ends (50- and
30-RACE, Clontech) in accordance with the manufacturer’s
protocol via Phusion Taq polymerase (Roche) and Human
retina or testis Marathon-Ready (Clontech) cDNA as a tem-
plate followed by sequence analysis. Primers for RT-PCR
were designed based on exons predicted by performing
blatp with the amino acid sequence in Q9UMZ3. Primer
sequences are provided in Table S1 available online. With
RT-PCRwe detected transcripts containing all exons encod-
ing Q9UMZ3.
Via 50RACE experiments with a primer that hybridizes to
the second exon of NM_001145026.1, additional exons
were identiﬁed and indications for splice variants in retina
and testis were obtained (Figure 2A, transcript numbers I
and II). Seven of these additional exons were predicted in
the Genscan entry NT019546.6.1 and others were not
annotated previously. With RT-PCR on retina marathon
cDNA, we identiﬁed two further transcripts, III and IV
(Figure 2A), the latter of which was also ampliﬁed from
testis marathon cDNA. To explore the presence of addi-
tional exons at the 50 end of the gene, we performed
50-RACE with a primer in the fourth predicted exon of
NT_019546.61. This resulted in a cDNA fragment contain-
ing two additional exons, exons 1 and 2 (transcript V in
Figure 2A). These exons do not contain a signiﬁcantThe Amopen reading frame and are therefore considered to be
part of the 50UTR of the PTPRQ gene. In total, 58 exons
of the PTPRQ gene were found to be present in alterna-
tively spliced transcripts. In addition to alternative splicing
of exons at the 50 end of the gene, exon 49 was found to be
alternatively spliced in both retina and testis RNA. This
exon encodes nine amino acids in the intracellular region
of PTPRQ. These amino acids are located N-terminal of the
phosphatase domain and are therefore unlikely to directly
affect the catalytic properties of the protein. However, it
cannot be excluded that the structure of the catalytic
domain differs between the two isoforms that lack or
contain these nine amino acids and that this alters the
catalytic properties of the phosphatase domain.
c12orf64, located upstream of NT_019546.61, encodes
an otogelin-like protein. Because otogelin is expressed in
inner ear8 and the protein encoded by c12orf64 was pre-
dicted to consist of extracellular domains only, we investi-
gated whether c12orf64 may be part of PTPRQ by RT-PCR
with a forward primer in c12orf64 and a reverse primer in
NT_019546.61. Because no PCR products were obtained,
there are so far no indications that PTPRQ and c12orf64
are part of the same gene.
In the rat, two different transmembrane isoforms of
PTPRQ are expressed in glomeruli and smooth muscles
cells and an intracellular isoform that lacks part of the
phosphatase domain. These isoforms result from alterna-
tive splicing and the use of an alternative promoter, respec-
tively.9 We did not further explore whether such isoforms
are present in man. The proteins encoded by the alterna-
tively spliced mRNAs indicated in the present study lead
to isoforms which differ by the number of FN3 domains
(Figure 2B).
To investigate the involvement of PTPRQ in the hearing
loss in families W04-083 and W07-0455, we performed
sequence analysis of the 58 exons and exon-intron bound-
aries of PTPRQ as described.3 Primer sequences and PCR
conditions are provided in Table S1. The nomenclature oferican Journal of Human Genetics 86, 604–610, April 9, 2010 605
Figure 2. PTPRQ Gene Characterization and Schematic Representation of PTPRQ Protein Structure
(A) Schematic overview of the gene organization for PTPRQ showing the exon structure of NM_001145026.1 and of the Genscan entry
NT019546.61 according to the UCSC genome browser (GRCh37). The exons encoding Q9UMZ3were determined by performing a Blatp
search in the UCSC genome browser with the protein sequence. Splice variants I, II, and V were detected in RACE experiments and
numbers III and IV in RT-PCR experiments. The orange colored exons indicate the open reading frame, which was determined with
the NCBI ORF ﬁnder and only ATG was considered as a start codon. Exon 49 was found to be alternatively spliced.
(B) Predictions of conserved domains of the identiﬁed alternatively spliced RNA, determined with the simple modular architecture
research tool (SMART). Isoforms differ in the number of FN3 domains and for isoforms II and III, 19 FN3 domains are predicted; for iso-
form IV 18, for isoform I 15, and for Q9UMZ3 17 FN3 domains. The alternatively spliced exon 49 encodes for amino acids within the
phosphatase domain. *The nomenclature of the indicated mutations is based on splice variant III and nomenclature based on the other
splice variants is given in Table 1.the mutations in this section is based on splice variant III,
and nomenclature based on the other splice variants is
given in Table 1. In individual II.6 of family W07-0455,
a homozygous nucleotide substitution, c.1491T>A in
exon 19, leads to a premature stop codon at position 497
of the protein (p.Tyr497X; Figure 3A). In individual II.1
of family W04-083, a homozygous missense mutation in
exon 19 was found, c.1369A>G, leading to the substitu-
tion of a glycine for an arginine at position 457 of the
protein (p.Arg457Gly, Figure 3A). The mutations cosegre-
gate with the disease in both families (Figure 3B) and
were not found in at least 125 ethnically matched controls
via an ampliﬁcation refractory mutation system (ARMS)
approach.Table 1. Nomenclature of PTPRQ Mutations for Alternatively Spliced
Splice Varianta Size of orf (bps)
Size Protein
(# of Amino Acids)
# of
Dom
I 6600 2200 15
II 7761 2587 19
III 7551 2517 19
IV 7503 2501 18
a The number of the transcripts correspond to the numbers in Figure 2A.
b The number of FN3 domains was determined with the Simple modular archite
606 The American Journal of Human Genetics 86, 604–610, April 9, 2The amino acid substitution p.Arg457Gly was analyzed
with polymorphism phenotyping (Polyphen) and sorting
intolerant from tolerant (SIFT). Polyphen predicted this
change to be probably damaging for protein function,
whereas SIFT predicted it to be tolerated. Alignment of
PTPRQ protein sequences of different species including
mouse, rat, chimpanzee, cow, and zebraﬁsh shows that
the arginine is conserved in four of these species but not
in zebraﬁsh, which has a leucine in this position. An align-
ment of part of the proteins is provided in Figure S1. The
mutated residue is located in the ﬁfth FN3 domain of splice
variant III; these extracellular domains are known to bind
ligands such as extracellular proteins and other molecules
including collagen and heparin, respectively, and alsoTranscripts and the Corresponding Isoforms
FN3
ainsb
Mutation W04-083 Mutation W7-0455
cDNA Protein cDNA Protein
c.418A>G R140G c.540T>A T180X
c.1579A>G R527G c.1701T>A T567X
c.1369A>G R457G c.1491T>A T497X
c.1321A>G R441G c.1442T>A T481X
cture research tool (SMART).
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Figure 3. Mutation Analysis of PTPRQ in arNSHI
Patients
(A) Partial PTPRQ sequences are shown for affected
members and normal controls. The predicted amino
acid changes and the surrounding amino acids are
indicated above the sequence. Mutated nucleotides
are marked by an arrowhead. As reference, sequence
NT_029419.12 was employed.
(B) Pedigrees and genotypes of families with homozy-
gous mutations in PTPRQ. The mutations cosegregate
with the hearing impairment.ligands on cells.10–12 An FN3 domain in the protein tyro-
sine phosphatase receptor J (PTPRJ) has been shown to
be involved in the formation of protein complexes and
its localization in the cell.13 Through the p.Arg457Gly
mutation, a big, hydrophilic, and positively charged amino
acid, is replaced by a small uncharged residue without a
side chain. Therefore, ionic interactions and other possible
interactions of the arginine residue in the wild-type PTPRQ
such as hydrogen bonds will be lost by themutation. Alter-
natively, protein localization may be affected.
The homozygous mutation in a homozygous region
indicates that the parents in family W07-0455 have a
common ancestor. To estimate the degree of relatedness,
we have used a genomic measure of individual autozygos-
ity, Froh, which is strongly correlated with the inbreeding
coefﬁcient.14 A set of individuals whose parents were ﬁrst
cousins had a mean Froh value of 0.108 (between 0.072
and 0.136). Three sibs of Dutch origin from a couple
with a common ancestor who lived ﬁve generations
previous exhibited a mean Froh of 0.018 (between 0.011
and 0.027). The two subjects of family W07-0455 had an
Froh of 0.009 and 0.016, which suggests that the common
ancestor of their parents lived at least ﬁve generations prior
to the present day.
Routine clinical examinations did not reveal any abnor-
malities other than inner ear dysfunction in the partici-
pating individuals. Hearing loss is bilateral, symmetric,
and sensorineural and probably was congenital in both
families. In family W07-0455, ﬁrst testing of individual
II.5 occurred only at 4 years of age (because of World
War II) and a hearing loss of 90–95 dB was measured.
Hearing loss in individual II.6 of this family was noticed
soon after birth but audiograms are available only from
older ages (Figures 4A and 4B). Both affected subjects did
not develop normal speech spontaneously. Furthermore,
progression of hearing loss from severe to profound was
reported from 30 years and 45 years onward by individuals
II.5 and II.6, respectively. Both affected children in family
W04-083 exhibit moderate hearing loss (Figures 4C and
4D) and did not pass the hearing screening at the age
of ~10 months. Linear regression analysis of longitudinalThe Amseries of pure tone audiograms could be performed for indi-
vidual II.1 and indicates signiﬁcant progression of the
hearing loss only for the left ear with annual threshold
deteriorations between 2.4 and 3.4 dB for the frequencies
0.25, 0.5, and 8 kHz. In early childhood, the hearing loss
in this family must have been less severe than in family
W07-455 as indicated by the fact that speech development
was normal in subject II.2 and only mildly impaired in
subject II.1, which is probably due to the cooccurrence of
recurrent otitis media with effusion in the ﬁrst 2 years
of life of this subject. Hearing aids were used by both
children from the age of 3.5 years onward. Normal otoa-
coustic emissions were measured in patient II.2 at the age
of 13 months. Otoscopic examination did not reveal any
abnormalities except otitis media in individual II.1 of
family W04-083. Electronystagmography in caloric and
rotatory testing15 demonstrated an impaired vestibular
function in the patients of both families. No responses
were measured for individuals II.5 and II.6 of family
W07-0455 at the ages of 57 and 55 years, respectively,
and both subjects reported delayed motor development
with ability to walk unaided only at 2 years of age.
Although this motor development was normal in the
affected individuals II.1 and II.2 of family W04-083, severe
hyporeﬂexia was diagnosed by electronystagmography at
the ages of 13 years and 7 years, respectively.
The expression pattern of PTPRQ was determined by
qPCR on cDNA from various fetal and adult human
tissues as described,3 with primers that amplify a fragment
encoding the intracellular region of PTPRQ (Table 1 and
Figure 5). Transcripts were detected in all but two fetal
tissues that were tested and was highest in fetal kidney, fol-
lowed by fetal lung and fetal cochlea. Transcript levels were
below detection level in fetal liver and fetal colon. In all
adult tissues that were tested, transcripts were detected
with the highest levels in lung and heart. These levels
were lower than in fetal cochlea that was included in the
same experiment for comparison. Clinical evaluations
did not indicate involvement of other organs than inner
ear in the disease. Renal functions were found to be normal
in laboratory testing of blood and urine for both families.erican Journal of Human Genetics 86, 604–610, April 9, 2010 607
Figure 5. PTPRQ Expression Profile
Relative PTPRQ mRNA expression as determined by quantitative
PCR in fetal (A) and adult (B) tissues. This was performed for adult
and fetal tissues in two separate experiments, so fetal cochlea was
included in both to be able to compare the expression levels. The
relative expression values were determined via the delta delta Ct
method. The highest expression levels are seen in fetal kidney,
fetal cochlea, fetal and adult lung, and adult heart.
Figure 4. Clinical Characterization of the DFNB84 Families
Audiograms of affected individuals of W07-0455 (A and B) and
W04-083 (C and D) at different ages. Only results for the left
ear are represented. Pure tone audiometry was performed in a
sound-treated room according to current clinical standards.Normal levels of sodium, potassium, chloride, and bicar-
bonate were found in blood and normal levels of urea
and creatinine in urine. Albumin was not detected in
urine. No retina abnormalities were observed in recent
funduscopy in the patients of family W07-0455. Both
patients of this family are hyperopic and in patient II.5
this is severe. However, this is unlikely to be associated
with the defects in PTPRQ, because the normal hearing
father was also severely hyperopic. There are no indica-
tions for abnormalities in lung function in both families.
The lack of symptoms in organs with relatively high
PTPRQ expression may point toward redundancy for
PTPRQ function. In addition, the relevant PTPRQ isoform
in these organs may not be affected by the mutations. In
human kidney, however, transcripts encoding the extracel-
lular region of PTPRQ have been identiﬁed.9
In mouse inner ear, a transmembranous Ptprq isoform
with both the extracellular region and the intracellular
region9 is likely to be the predominant isoform because
staining patterns with antibodies directed against these
regions exhibit similar staining patterns in rodents.16
This is corroborated by similar phenotypes of mice in
which the PTPRQ gene has been targeted by deletions in
the regions that encode either the transmembrane domain
or the phosphatase domain.7 These mice demonstrate that
Ptprq is required for normal maturation of the hair
bundles in the basal region of the cochlea. In this part
of the cochlea, both inner and outer hair cells exhibit
varying degrees of disorganization already in early post-
natal stages, whereby the phenotype in inner hair cells608 The American Journal of Human Genetics 86, 604–610, April 9, 2precedes that of outer hair cells. In the inner hair cells,
stereocilia are missing or fused and in outer hair cells these
are severely shortened. In adult mice with a targeted Ptprq
gene, hair cells have completely degenerated or even the
complete organ of Corti is missing.7 In the apical part of
the cochlea of mice homozygous for the deletions, the
gross structure of the organ of Corti is normal and no
loss of hair cells was seen in this cochlear region or in
the vestibular organs although shaft connectors are
missing.7 There was no Preyer reﬂex to tone bursts up to
105 dB at 20 kHz at 3 months of age in the Ptprq/
mice, but the hearing loss in these mice has not been
characterized further. The mice do not exhibit behavioral
abnormalities associated with vestibular dysfunction.7
This suggests that Ptprq is not essential for vestibular func-
tion in mice; however, it is not indicated whether further
tests on vestibular function have been performed. In
contrast to the apparently normal vestibular function in
mice, patients with PTPRQ mutations displayed vestibular
dysfunction already in infancy or early childhood. It can
not be excluded that the dysfunction of vestibular hair010
cells in mice is mild and only detectable upon functional
testing. Also, the cochlear defects associated with PTPRQ/
Ptprq defects may be more severe in humans than in mice
because the complete cochlea seems to be affected in
humans, as indicated by hearing loss in all frequencies
(Figure 4).
PTPRQwas initially identiﬁed as a protein tyrosine phos-
phatase (PTPase) that exhibits increased expression in a
rat model of glomerular nephritis.17 In further analyses,
PTPRQ was found to have low PTPase activity and mainly
functions as a phosphatidylinositol phosphatase (PIPase)
and PI(4,5)P2 was efﬁciently dephosphorylated.
9,18 In
hair cells, PI(4,5)P2 is essential for mechanotransduction
and both fast and slow adaptation. PI(4,5)P2 is concen-
trated in the distal part of the hair bundle and there is
a PIP2-free zone at the base of the bundle.
19 Because Ptprq
was found to be concentrated at the base of the hair bundle
with a decaying gradient from base to apex in cochlear hair
cells and a subset of vestibular hair cells, it was suggested
that Ptprq PIPase activity maintains the PIP2-free zone
at the base of the stereocilia.7,16,19 Furthermore, it was
suggested that the compartmentalization of Ptprq is due
to transport of the enzyme toward the base of stereocilia
by myosin VI.16 PTPRQ and Myosin VI are thought to
form a complex that is essential for tethering of the
membrane to the cytoskeleton in the tapered ankle region
of stereocilia.16
The truncating mutation in family W07-0455 can be
predicted to affect both the formation of shaft connectors
and the PIPase activity of PTPRQ. Whether this is also true
for the missense mutation detected in family W04-083 is
more difﬁcult to predict. In infancy and childhood, the
phenotype is less severe than in family W07-0455, which
suggests that PTPRQ with the Arg457Gly mutation has
residual activity.
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